MORRIS PLAINS, N.J., Sept. 17, 2008 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today provided a detailed review and update of the Company's clinical pipeline, including plans for future clinical and research developments at the Company's Research and Development Day held at the Waldorf Astoria Hotel in New York City. An archived version of today's webcast will be available through October 16, 2008 on the R&D Day page of the Investor Relations section of the Company's website at www.immunomedics.com.
